<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320121</url>
  </required_header>
  <id_info>
    <org_study_id>02-2020-005</org_study_id>
    <nct_id>NCT04320121</nct_id>
  </id_info>
  <brief_title>Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults</brief_title>
  <official_title>Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
      the effects of Nelutri™on muscle strength, muscle mass, and muscle function in healthy adults
      for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study has indicated that Nelutri™ may increase muscle mass and strength.
      Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to
      investigate the effects of Nelutri™on muscle strength, muscle mass, and muscle function in
      healthy adults; the safety of the compound are also evaluate. The Investigators examine the
      peak torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass,
      physical performance, and metabolic parameters at baseline, as well as after 6 and 12 weeks
      of intervention. Eighty adults were administered either 2,000 mg of Nelutri™ or a placebo
      each day for 12 weeks;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>12 weeks</time_frame>
    <description>the peak torque at 60°/s knee extension (/kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>appendicular skeletal mass/(height x height)</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appendicular skeletal mass/weight x 100</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Mass Index/(height x height)</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Kinase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Creatinine Kinase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Lactate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensional three levels (EQ-5D-3L)</measure>
    <time_frame>12 weeks</time_frame>
    <description>an index of life quality, minimum, maximum values (-0.171, 1), higher scores mean a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Muscular Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Nelutri™ group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Nelutri™ for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nelutri™</intervention_name>
    <description>Nelutri™ 2,000 mg/day for 12 weeks</description>
    <arm_group_label>Nelutri™ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo 2,000 mg/day for 12 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;110% of the standard lean body mass as measured using the body composition analyzer

          -  Body-mass index (BMI) ranging from 18.5 to 30.0 kg/m2

          -  Those who have an average protein intake of 60 g or more/day.

        Exclusion Criteria:

          -  Abnormal liver or renal function (i.e., serum aminotransferase activity &gt; 60 IU/L and
             serum creatinine concentrations &gt; 1.2 mg/dL)

          -  Diabetes (diagnosed clinically or fasting glucose level &gt; 126 mg/dL)

          -  History of fracture during the previous year

          -  Uncontrolled hypertension

          -  History of serious cardiac disease such as angina or myocardial infarction

          -  History of gastrectomy

          -  History of medication for psychiatric disease

          -  Administration of oriental medicine including herbs within the past 4 weeks

          -  Evidence of relatively high skeletal mass (more than 110% of the standard lean body
             mass as measured using the body composition analyzer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Yeoup Lee, MD</last_name>
    <phone>360-1442</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye LI Lee</last_name>
    <phone>360-1442</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Yeoup Lee, Pf.</last_name>
      <phone>82-55-360-2860</phone>
      <email>saylee@pnu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

